Arcturus Therapeutics Holdings INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Arcturus Therapeutics reported a significant revenue decline in Q3 2025, primarily due to its COVID-19 vaccine transitioning to commercial phase, while facing an FDA delay for its KOSTAIVE BLA submission and ongoing material weakness in internal controls.
NASDAQ
Arcturus Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D expenses, as its COVID-19 vaccine KOSTAIVE received EU marketing authorization and key therapeutic programs advanced.
NASDAQ
Arcturus Therapeutics announces its Q1 2025 financial results, emphasizing the commercialization of KOSTAIVE and progress in its mRNA therapeutics pipeline.
NASDAQ
Arcturus Therapeutics announced its Q3 2024 financial results, highlighted by the commercial launch of its self-amplifying mRNA COVID-19 vaccine in Japan and progress in its clinical programs.
NASDAQ
Arcturus Therapeutics announced its second quarter 2024 financial results, highlighting progress in its mRNA vaccine and therapeutic programs, including a significant increase in collaboration revenue.
NASDAQ
Arcturus Therapeutics reported a net loss for Q1 2024, while highlighting progress in its mRNA vaccine and therapeutic programs, including key updates on its collaboration with CSL Seqirus.